Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals

E Degasperi,G.M Saracco,A Ciancio,G Troshina,G.P Caviglia,R D'Ambrosio,A Nicolosi,P Fariselli,P Lampertico

doi:10.1016/j.dld.2022.08.002

Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals

E Degasperi, G.M Saracco + Show 7 more

https://doi.org/10.1016/j.dld.2022.08.002

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Oct 1, 2022

Affiliation: Ospedale Maggiore, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Turin, Fondazione Ricerca Molinette, University of Milan

#Protein Induced By Vitamin K Absence Or antagonist-II #Prediction Of Hepatocellular Carcinoma Development + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction: Patients with hepatitis C virus (HCV)-related cirrhosis witha a sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin k absence or antagonist-II (PIVKA-II) showed promising results as HCC predictive biomarker.

Full Text